The WHO is based in Geneva
Keystone / Martial Trezzini
Switzerland has confirmed its participation in the World Health Organization (WHO)’s COVAX initiative aimed at ensuring equitable access to Covid-19 vaccines when they are approved.
The government confirmed on September 18 its participation in the initiative to secure vaccines for 20% of the population, it said in a press releaseExternal link on Friday.
“In order to secure a fair distribution of Covid-19 vaccines across the globe, nations across the world have formed the COVAX initiative (COVID-19 Vaccine Global Access Facility) and created a pooled procurement mechanism,” it explained.
More than 60 higher income economies have joined COVAX, according to a September 21 WHO press releaseExternal link. It said more were expected to sign up in coming days. They are joined by 92 low- and middle-income economies eligible for support for the procurement of vaccines. The aim is to procure two billion doses of vaccines from a range of manufacturers by the end of 2021.
Funds, procurement
Switzerland will contribute CHF20 million ($22 million), according to the government press release. In addition, so-called self-financing countries – that is, higher-income countries such as Switzerland – may contribute additional funds to secure Covid-19 vaccines for their own populations.
Switzerland has also signed a contract with the US firm Moderna Therapeutics for the purchase of 4.5 million doses of vaccine and is in conversation with other vaccine manufacturers. Bern says joining the COVAX initiative is a complementary measure to these procurement efforts.
COVAX is co-led by the Vaccine Alliance (Gavi), the Coalition for Epidemic Preparedness Innovations (CEPI) and the WHO. Switzerland has been among the initiative’s supporters from the beginning and, together with Singapore, has “led a group of likeminded countries to supervise the development of the COVAX Facility from the perspective of self-financing countries”.
Popular Stories
More
Multinational companies
Azeri fossil-fuel cash cow brings controversy to Switzerland
Swiss price watchdog slams excessive prices for generic medicines
This content was published on
The cheapest generic medicines available in Switzerland are more than twice as expensive as in other countries, according to a study by the Swiss price watchdog.
Nature should not figure in net zero calculations: academic study
This content was published on
The natural removal of CO2 from the atmosphere by forests or oceans should not be included in the net-zero balance of climate protection measures, argue researchers.
This content was published on
None of the 15 major Swiss retail banks is meeting international climate and biodiversity targets, according to a ranking by WWF Switzerland.
This content was published on
Nestlé's new CEO Laurent Freixe, has presented plans for the future of the world's largest food company, after his first few weeks in office.
Swiss foreign minister calls on Moscow to end Ukraine war
This content was published on
It's high time Moscow ended its war against Ukraine, Swiss foreign minister Ignazio Cassis tells the UN Security Council.
This content was published on
The only alternative to the UN Palestinian agency’s work in Gaza is to allow Israel to run services there, Philippe Lazzarini, UNRWA Commissioner-General, told reporters in Geneva on Monday.
Study reveals food culture differences between Switzerland and neighbours
This content was published on
Three-quarters of Swiss people consider eating to be a pleasurable, social activity, a new survey reveals. Healthy eating, however, plays a much less important role, it found.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
Opinion
More
Covid-19 vaccine: when, and for whom?
This content was published on
It’s the question we all want an answer to: when will there be a vaccine against Covid-19? And how is fair access being negotiated?
Switzerland pre-orders 4.5 million doses of Covid-19 vaccine
This content was published on
The Swiss government has signed a deal with US biotech firm Moderna to secure early access to 4.5 million doses of a Covid-19 vaccine currently in development.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.